Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: cancer  treatment  medical  medicine  fda  ctca  educational  awareness  multivu  8295651  wine  culinary  food  cooking  restaurant  josep  roca  forum  michel  bettane  barcelona  multivu  7948051  roche  american  association  clinical  chemistry  lab  science  aacc  testing  healthcare  multivu  7889151  science  technology  health  medical  award  biologist  yoshinori  ohsumi  research  cure  multivu  7856351  biopharmx  violet  iodine  fbc  menstruation  hormones  women  health  multivu  7378951  college  american  pathologists  meeting  2014  cap14  cancer  molecular  genetic  testing  pathology  medicine  multivu  7270051  asuragen  fragilex  syndromes  autism  xpansion  interpreter  genetic  test  pregnancy  children  women  health  multivu  60719  phoenix  childrens  hospital  molecular  medicine  institute  health  drug  therapy  genetics  multivu  59399  childrens  hospital  philadelphia  lymphoma  neuroblastoma  cancer  medication  treatment  genes  therapy  health  multivu  50776  progensa  pca3  assay  molecular  test  prostate  cancer  repeat  biopsies  genprobe  fda  healthcare  multivu  53530  veripsych  rules-based  medicine  rbm  schizophrenia  diagnostic  test  tool  healthcare  multivu  46237 
Search // molecular
Results 1-11 of 11 for ' molecular ' (1 seconds)
Cancer Treatment Centers of America® (CTCA), a national network of comprehensive cancer care hospitals and outpatient care centers, and Foundation Medicine, a leading molecular insights company that recently received FDA approval for its FoundationOne CDx™ genomic test, today announced the launch of a collaborative educational campaign designed to heighten awareness of the promise of precision medicine and the role that advanced genomic testing plays in helping identify treatments best suited for individual patients. To view the multimedia release go to: https://www.multivu.com/players/English/8295651-cancer-treatment-centers-of-america-foundation-medicine-precision-cancer-treatment/
Categories // Miscellaneous 
Added: 2180 days ago by MultiVuVideos
Runtime: 0m27s | Views: 606 | Comments: 4
Not yet rated
 

 

 

Barcelona is hosting the third edition of the Wine & Culinary International Forum today, a biennial international conference dedicated to food and wine pairing promoted by Bodegas Torres. Over 250 professionals, including sommeliers, restaurant owners, distributors and journalists from almost 20 different countries, participated in the event. Celebrated in the Palau de Congressos de Catalunya, it provided a forum in which to reflect and discuss the complementary relationship between wine and food under the heading “Wine and World Cuisines.” The president of Bodegas Torres, Miguel A. Torres, opened the event, which featured talks, tastings and culinary demonstrations by a total of 20 national and international experts who are highly regarded in their fields. Among them, Josep Roca, sommelier at El Celler de Can Roca; the award winning wine-writer and journalist Sarah Jane Evans MW, an expert in Spanish wines as well as the former Chairman of the Institute of Masters of Wine; the prestigious French enologist Pascal Chatonnet, one of the leading researchers into the microbiological factors involved in the interaction between wine and oak; Canadian researcher François Chartier, a pioneer in the aromatic science of molecular food matching since 2004 and author of Taste Buds and Molecules, world’s best innovative food 2010; the renowned French wine critic Michel Bettane; and the endocrinologist Dr. Francisco Tinahones, a researcher at the University of Malaga. To view the multimedia release go to: http://www.multivu.com/players/uk/7948051-torres-wine-culinary-international-forum/
Categories // Miscellaneous 
Added: 2725 days ago by MultiVuVideos
Runtime: 2m46s | Views: 649 | Comments: 0
Not yet rated
 

 

 

Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence at the American Association for Clinical Chemistry (AACC) 2016 Clinical Lab Expo today by featuring several next-generation diagnostic testing platforms and a new virtual reality experience that gives attendees an “under the hood” look at a lab of the future and an innovative concept Roche calls the “Roche connected lab.” The virtual reality theater will enable attendees to view samples moving through a virtual lab equipped with various configurations of Roche automation, chemistry/immunoassay platforms and molecular diagnostics systems, as well as connections to third-party platforms. The actual Roche systems that are part of the connected lab concept will also be on display in the booth. To view the multimedia release go to: http://www.multivu.com/players/English/7889151-roche-aacc-2016/
Categories // Miscellaneous 
Added: 2795 days ago by MultiVuVideos
Runtime: 3m16s | Views: 679 | Comments: 0
Not yet rated
 

 

 

As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy. Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here. “Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.” To view the multimedia release go to: http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
Categories // Miscellaneous 
Added: 2849 days ago by MultiVuVideos
Runtime: 1m37s | Views: 705 | Comments: 0
Not yet rated
 

 

 

BioPharmX Corporation (OTCQB: BPMX) today announced the availability of Violet™ iodine, a new, once-daily pill for relief of premenstrual breast discomfort. The first-of-its-kind product is based on the latest molecular iodine technology designed to help free women from the burden of breast discomfort by addressing the underlying causes of a condition known as fibrocystic breast condition (FBC), with the added benefit of promoting breast health for women of reproductive age.* *These statements have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7378951-biopharmx-introducing-violet-iodine-premenstrual-breast-discomfort/
Categories // People and Blog  Business 
Added: 3397 days ago by MultiVuVideos
Runtime: 1m8s | Views: 620 | Comments: 2
   
 

 

 

New science in molecular and genetic testing for breast, colon, and prostate cancer, as well as leukemia, will be among the special features at the College of American Pathologists’ annual scientific and education meeting, CAP’14—THE Pathologists’ Meeting, Sept. 7-10 at the Hyatt Regency in Chicago. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270051-college-of-american-pathologists-cap-14-what-s-next-in-cancer-testing/
Categories // Science and Technology 
Added: 3516 days ago by MultiVuVideos
Runtime: 5m19s | Views: 701 | Comments: 0
Not yet rated
 

 

 

Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ. To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
Added: 4025 days ago by MultiVuVideos
Runtime: 3m22s | Views: 1855 | Comments: 0
Not yet rated
 

 

 

Phoenix Children’s Hospital announced the creation of the Ronald A. Matricaria Institute of Molecular Medicine today, with the goal to unlock genetic codes and develop drug therapies in real time to improve the outcome for thousands of young patients. To view Multimedia News Release, go to http://www.multivu.com/mnr/59399-phoenix-children-s-hospital-visionary-institute-of-molecular-medicine
Categories // Family 
Added: 4130 days ago by MultiVuVideos
Runtime: 6m28s | Views: 3228 | Comments: 0
Not yet rated
 

 

 

A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma. A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia. “We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.” To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Categories // People and Blog 
Added: 4333 days ago by MultiVuVideo
Runtime: 4m41s | Views: 4475 | Comments: 0
Not yet rated
 

 

 

Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy. To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
Categories // News and Politics 
Added: 4425 days ago by MultiVuVideo
Runtime: 2m41s | Views: 6721 | Comments: 0
Not yet rated
 

 

 

Rules-Based Medicine, Inc. (RBM), today announced the widespread commercial availability of VeriPsych™, the first and only blood-based diagnostic test to aid in confirming the diagnosis of recent onset schizophrenia, a potentially devastating and costly mental illness that affects about 24 million people worldwide. VeriPsych is an innovative molecular diagnostic tool designed to complement the healthcare provider’s clinical impression. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/rulesbasedmedicine/46237/
Categories // People and Blog 
Added: 4920 days ago by MultiVuVideos
Runtime: 4m9s | Views: 10337 | Comments: 0
Not yet rated
 

 

 

Page 1 of 1  |  Go to page   



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2024 ClipMoon.com. All rights reserved.